We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

262 hedge funds and large institutions have $2.99B invested in Pacira BioSciences in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 95 increasing their positions, 84 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $6.13M | Put options by funds: $3.09M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

13% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 84

1.49% less ownership

Funds ownership: 113.64% → 112.14% (-1.5%)

3% less funds holding

Funds holding: 270 → 262 (-8)

14% less capital invested

Capital invested by funds: $3.49B → $2.99B (-$500M)

20% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 30

Holders
262
Holders Change
-8
Holders Change %
-2.96%
% of All Funds
4.56%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
24
Increased
95
Reduced
84
Closed
30
Calls
$6.13M
Puts
$3.09M
Net Calls
+$3.05M
Net Calls Change
-$2.42M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$31.9M
2
Macquarie Group
Macquarie Group
Australia
+$26.8M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$19.2M
4
Two Sigma Investments
Two Sigma Investments
New York
+$17.6M
5
SPPAM
Summit Partners Public Asset Management
Massachusetts
+$14.3M

Top Sellers

1
Wells Fargo
Wells Fargo
California
-$49M
2
BlackRock
BlackRock
New York
-$32.6M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$27.6M
4
Renaissance Technologies
Renaissance Technologies
New York
-$16.1M
5
FCM
Frontier Capital Management
Massachusetts
-$14.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
BSA
176
Braun Stacey Associates
New York
$336K -$6.51M -102,875 -95%
BFG
177
Bouchey Financial Group
New York
$334K – – –
Rafferty Asset Management
178
Rafferty Asset Management
New York
$328K +$54.9K +867 +19%
Teacher Retirement System of Texas
179
Teacher Retirement System of Texas
Texas
$321K +$51.1K +808 +18%
TAM
180
Tocqueville Asset Management
New York
$303K -$633 -10 -0.2%
SW
181
SVB Wealth
Massachusetts
$303K – – –
OSAM
182
O'Shaughnessy Asset Management
Connecticut
$286K -$633 -10 -0.2%
ECM
183
Everence Capital Management
Indiana
$285K – – –
AAM
184
Azzad Asset Management
Virginia
$284K -$3.92K -62 -1%
Walleye Trading
185
Walleye Trading
New York
$275K +$287K +4,531 New
CAM
186
ClariVest Asset Management
California
$271K – – –
FMT
187
First Mercantile Trust
Tennessee
$270K -$15.6K -246 -5%
MYIA
188
Mount Yale Investment Advisors
Colorado
$242K +$36.9K +583 +17%
Zurich Cantonal Bank
189
Zurich Cantonal Bank
Switzerland
$241K – – –
II
190
Inspire Investing
Idaho
$240K +$7.6K +120 +3%
SAM
191
Shell Asset Management
Netherlands
$239K +$159K +2,518 +178%
SAM
192
Sawgrass Asset Management
Florida
$229K -$154K -2,430 -39%
RJFSA
193
Raymond James Financial Services Advisors
Florida
$228K -$97.7K -1,544 -29%
MCM
194
Maryland Capital Management
Maryland
$213K -$35.3K -557 -14%
NCM
195
Next Capital Management
New York
$212K – – –
AIP
196
Ameritas Investment Partners
Nebraska
$210K – – –
EWM
197
Evercore Wealth Management
New York
$207K – – –
HighTower Advisors
198
HighTower Advisors
Illinois
$203K +$570 +9 +0.3%
KBC Group
199
KBC Group
Belgium
$196K – – –
CAPTRUST Financial Advisors
200
CAPTRUST Financial Advisors
North Carolina
$190K -$304K -4,801 -61%
6 7
8
9 10

PCRX Hedge Fund Activity: Q2 2021 in Review

262 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2021, worth a combined $2.99B — down 14% from $3.49B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PCRX and 24 opened new positions — a net loss of 6 holders — while 84 trimmed existing stakes and 95 added.

The largest buyer was Westfield Capital Management, adding an estimated $31.9M. The largest seller was Wells Fargo, cutting an estimated $49M.

  • 262 institutional investors held Pacira BioSciences (PCRX) as of Q2 2021, down from 270 in Q1 2021.
  • Funds reported $2.99B of Pacira BioSciences stock for Q2 2021, down 14% quarter-over-quarter.
  • 24 funds opened new Pacira BioSciences positions in Q2 2021 and 30 closed out, a net change of -6 holders.
  • The largest Pacira BioSciences buyer in Q2 2021 was Westfield Capital Management, an estimated $31.9M added.
  • The largest Pacira BioSciences seller in Q2 2021 was Wells Fargo, an estimated $49M sold.

Based on aggregated 13F filings for Q2 2021.